ABSTRACT
OBJECTIVE:To observe the efficacy and safety of Zhenqi fuzheng granule combined with dasatinib in the treat-ment of BCR/ABL positive leukemia. METHODS:40 patients with BCR-ABL positive chronic myeloid leukemia or PH-positive acute lymphoblastic leukemia were randomly divided into control group(20 cases)and observation group(20 cases). Control group received Dasatinib tablet,CML patients in chronic period received 100 mg,once a day,orally,morning or evening;CML patients in acceleration period and blastic period received 140 mg,once a day,orally,morning or evening,swallow whole,no cut or crushed. Observation group additionally received 15 g of Zhenqi fuzheng granule,twice a day. The treatment course for both groups was 24 months. Hematologic response,cytogenetic response and molecular biological response in 2 groups were observed, fatality rate,mean follow-up time and the incidence of adverse reactions were followed-up. RESULTS:CCR in observation group was significantly higher than control group,mean follow-up time was longer than control group,CCR median time was significant-ly shorter than control group,the incidence of adverse reactions and fatality rate were significantly lower than control group,the differences were statistically significant(P0.05). CONCLUSIONS:Zhenqi fuzheng granule combined with dasatinib is superior to dasat-inib alone in proving hematologic response and safety in the treatment of BCR-ABL positive leukemia,and similar in cytogenetic response and molecular biological response.
ABSTRACT
Objective To observe the synergetic action of Zhenqi Fuzheng granule in prevention and treatment of critically ill patients with severe infection. Methods A retrospective study was conducted. 154 cases with critical illness were enrolled in the First People's Hospital of Baiyin in Gansu Province from January 2009 to December 2013. The control group consisted of 76 cases and only basic treatments were given;in the treatment group, there were 78 cases,besides the basic treatments,they also taken nasal feeding of Zhenqi Fuzheng granule 5 g twice a day,7 days constituting for 1 therapeutic course,a total of 1-3 courses. The incidences of pulmonary infection, urinary tract infection,deep venous catheter-related infections,rate of using antibiotics,fatality rate,infection relapse rate,disease course,pathogen flora distribution were observed in the two groups. Results Compared with the control group,the rates of lung infection,urethral infection,deep vein catheter-related infection,the rate of using antibiotics, fatality rate,infection relapse rate,the discovery rates of drug resistant Acinetobacter baumannii,Pseudomonas aeruginosa,Stenotrophomonas maltophilia,Staphylococcus aureus,and Blastomyces albicans were obviously reduced in treatment group〔lung infection:15.38%(12 cases)vs. 47.37%(36 cases),urethral infection:7.69%(6 cases) vs. 23.68%(18 cases),deep vein catheter infection:5.13%(4 cases)vs. 18.42%(14 cases),antibacterial drug using rate:48.72%(38 cases)vs. 77.63%(59 cases),fatality rate:10.26%(8 cases)vs. 18.42%(14 cases),infection relapse rate:28.21%(22 cases)vs. 48.68%(37 cases),the discovery rate of Acinetobacter baumannii:3.85%(3 cases) vs. 11.84%(9 cases), of Pseudomonas aeruginosa:2.56%(2 cases) vs. 9.21%(7 cases), of Stenotrophomonas maltophilia:5.13%(4 cases)vs. 13.16%(10 cases),of Staphylococcus aureus:5.13%(4 cases) vs. 6.58%(5 cases),of Blastomyces albicans:6.41%(5 cases)vs. 10.52%(8 cases),all P<0.05〕;the therapeutic course was obviously shortened(day:5.79±1.89 vs. 13.65±2.73,P<0.05). Conclusion In critically ill patients with severe infection,treatment of Zhenqi Fuzheng granule can reduce the incidences of severe lung infection, urinary tract infection,deep venous catheter-related infection,the 5-year relapse rate,fatality rate,and shorten the therapeutic course,lower the usage of antibiotics and detection rate of drug-resistant bacteria,therefore,clinically it is effective in such patients.